Célèste Lebbé
Impact in
- Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Polyomavirus and related diseases
- Immunology top 0.02%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 370
- Cancer Immunotherapy and Biomarkers 115
- Cutaneous Melanoma Detection and Management 110
- CAR-T cell therapy research 73
- Viral-associated cancers and disorders 61
- Polyomavirus and related diseases 52
- Dermatology 74
- Co-authors
- Omid Hamid (18 shared papers)Jedd D. Wolchok (18 shared papers)Jeffrey S. Weber (12 shared papers)Frank Stephen Hodi (10 shared papers)Axel Hoos (6 shared papers)Michele Maio (13 shared papers)Steven J O'Day (5 shared papers)Rachel W. Humphrey (2 shared papers)
- Journals
- European Journal of Cancer (66 papers)Annals of Oncology (56 papers)Melanoma Research (25 papers)British Journal of Dermatology (25 papers)Journal of the European Academy of Dermatology and Venereology (24 papers)
- Partner nations
- FranceUnited StatesItaly
In The Last Decade
Célèste Lebbé
610 papers receiving 71.0k citations
Célèste Lebbé's Hit Papers
Peers
Comparison fields: 5 of 170
- Oncology 47.1k
- Immunology 18.5k
- Molecular Biology 20.7k
- Cancer Research 4.0k
- Dermatology 2.5k
Countries citing papers authored by Célèste Lebbé
This map shows the geographic impact of Célèste Lebbé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Célèste Lebbé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Célèste Lebbé more than expected).
Fields of papers citing papers by Célèste Lebbé
This network shows the impact of papers produced by Célèste Lebbé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Célèste Lebbé. The network helps show where Célèste Lebbé may publish in the future.
Co-authors
The 25 scholars most cited alongside Célèste Lebbé, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 651 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma Hit paper breakdown → | 2010 | 12635 |
| 2 | Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation Hit paper breakdown → | 2011 | 6388 |
| 3 | Nivolumab in Previously Untreated Melanoma without BRAF Mutation Hit paper breakdown → | 2014 | 4679 |
| 4 | Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2017 | 4597 |
| 5 | Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma Hit paper breakdown → | 2011 | 3746 |
| 6 | Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2019 | 2848 |
| 7 | Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria Hit paper breakdown → | 2009 | 2660 |
| 8 | Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma Hit paper breakdown → | 2017 | 1783 |
| 9 | Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma Hit paper breakdown → | 2014 | 1551 |
| 10 | Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial Hit paper breakdown → | 2015 | 1129 |
| 11 | Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy Hit paper breakdown → | 2016 | 1099 |
| 12 | Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma Hit paper breakdown → | 2019 | 1048 |
| 13 | Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Hit paper breakdown → | 2009 | 1033 |
| 14 | Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial Hit paper breakdown → | 2016 | 1024 |
| 15 | Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2015 | 1016 |
| 16 | Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study Hit paper breakdown → | 2014 | 836 |
| 17 | Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial Hit paper breakdown → | 2017 | 593 |
| 18 | Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study Hit paper breakdown → | 2017 | 536 |
| 19 | Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma Hit paper breakdown → | 2017 | 532 |
| 20 | Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis Hit paper breakdown → | 2017 | 496 |
About Célèste Lebbé
Célèste Lebbé is a scholar working on Oncology, Dermatology, Immunology, Epidemiology and Molecular Biology, having authored 651 papers that have together received 72.8k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (115 papers), Melanoma and MAPK Pathways (115 papers), Cutaneous Melanoma Detection and Management (110 papers), CAR-T cell therapy research (73 papers), Viral-associated cancers and disorders (61 papers), Polyomavirus and related diseases (52 papers), Immunotherapy and Immune Responses (50 papers) and Nonmelanoma Skin Cancer Studies (47 papers). The work is most often cited by research in Oncology (47.1k citations), Immunology (18.5k citations), Molecular Biology (20.7k citations), Cancer Research (4.0k citations) and Dermatology (2.5k citations). Célèste Lebbé has collaborated with scholars based in France, United States and Italy. Frequent co-authors include Omid Hamid, Jedd D. Wolchok, Jeffrey S. Weber, Frank Stephen Hodi, Axel Hoos, Michele Maio, Steven J O'Day, Rachel W. Humphrey, Jean‐Jacques Grob and Michael Binder. Their work appears in journals such as European Journal of Cancer, Annals of Oncology, Melanoma Research, British Journal of Dermatology and Journal of the European Academy of Dermatology and Venereology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.